Abstract 105P
Background
Cetuximab-based infusional 5-FU regimens are approved for the first-line treatment of mCRC in 116 countries. The OPTIM1SE study observed long-term real-world outcomes of these regimens in routine practice in Australia, South Korea, Malaysia, Singapore, Taiwan, Vietnam, Russia, Lebanon, and Saudi Arabia.
Methods
OPTIM1SE was a prospective, open-label, observational study. Patients with untreated KRAS wild-type mCRC and distant metastases were treated per the locally approved label and monitored for 3 years via hospital, laboratory, and other records. The primary endpoint was overall response rate (ORR) per RECIST 1.1. Safety and other efficacy outcomes were secondary endpoints.
Results
From 19 Nov 2013 to 30 Jun 2016, 520 patients were enrolled by 51 sites. Patients were mostly male (61.2%) with a mean age of 58.5 (±12.0) years; 1.7% were BRAF mutated; 420 patients were treated with FOLFIRI-based regimens and 94 with FOLFOX. The most common primary tumor site was rectum (38.8%) with liver metastases (65.0%). ORR was 45.4% (95% CI, 41.1%-49.7%), including 26 patients (5.0%) with a complete response. Median progression-free survival was 9.9 months (95% CI, 8.2-11.0); median overall survival (mOS) was 30.8 months (95% CI, 27.9-33.6). Patients receiving FOLFIRI-based regimens had better outcomes than those on FOLFOX, including increased ORR (48.6% vs 34.0%) and mOS (31.3 vs 28.6 months). Higher mOS was also associated with tumors of left- rather than right-sided origin (HR 0.69 [95% CI, 0.49-0.99]), and higher ORR with liver metastases compared to all other metastases (55.4% vs 40.2%). Adverse events were consistent with the known safety profile of cetuximab. The most common treatment-related adverse events (TRAE) were rash (20.2%), dermatitis acneiform (16.5%), and paronychia (13.7%); 2.1% of patients had a serious TRAE.
Conclusions
Cetuximab-based 5-FU regimens were effective in treating patients with mCRC, particuarly in those with left-sided disease origin and with liver metastases only, in routine practice. FOLFIRI-based cetuximab regimens were more common and showed improved outcomes over FOLFOX. Our findings are consistent with recent studies.
Clinical trial identification
Editorial acknowledgement
Medical editorial asssistance provided by Kristen Perry and Tim Stentiford, CMPP, of ClinicalThinking, part of Nucleus Global, and was funded by Merck Pte. Ltd.
Legal entity responsible for the study
Merck Pte. Ltd.
Funding
Merck Pte. Ltd.
Disclosure
T.W. Kim: Research grant/Funding (institution): Merck Serono; Research grant/Funding (institution): Sanofi. J.B. Ahn: Research grant/Funding (institution): Sanofi; Research grant/Funding (institution): Boryung. G.F. Ho: Honoraria (self): Roche; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy, Research grant/Funding (institution): Eli Lilly; Research grant/Funding (institution): Merck Sharp & Dohme; Research grant/Funding (institution): Regeneron; Research grant/Funding (institution): Astellas; Research grant/Funding (institution): AB Science; Research grant/Funding (institution): Tessa Therapeutics; Travel/Accommodation/Expenses: Eisai; Travel/Accommodation/Expenses: AstraZeneca; Full/Part-time employment: University Malaya Medical Centre; Full/Part-time employment: UM Specialist Centre. L.T. Anh: Honoraria (self), Honoraria (institution), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Merck KGaA; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Roche; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: MSD; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Bayer; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Pfizer; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Novartis. S. Temraz: Honoraria (self), Travel/Accommodation/Expenses: BMS; Honoraria (self), Travel/Accommodation/Expenses: Amgen; Advisory/Consultancy, Travel/Accommodation/Expenses: Merck KGaA; Advisory/Consultancy, Travel/Accommodation/Expenses: MSD. M. Burge: Advisory/Consultancy: Merck KGaA. C. Chua: Research grant/Funding (institution): MSD; Travel/Accommodation/Expenses: AstraZeneca; Travel/Accommodation/Expenses: Sanofi; Travel/Accommodation/Expenses: Merck KGaA. J. Huang: Full/Part-time employment: Merck Pte Ltd. Y.S. Park: Advisory/Consultancy: Merck KGaA; Full/Part-time employment: Samsung Medical Center. All other authors have declared no conflicts of interest.
Resources from the same session
34P - Clinical significance of neoadjuvant dose-dense chemotherapy for II and III stage breast cancer: A meta-analysis of published studies
Presenter: Meng chen Liu
Session: e-Poster Display Session
35P - Pathological response to weekly nabpaclitaxel and carboplatin followed by anthracycline regimen in triple negative breast cancer
Presenter: Goteti Sharat Chandra
Session: e-Poster Display Session
36P - Survival in patients with contralateral breast cancer
Presenter: Sergey Kamishov
Session: e-Poster Display Session
37P - Correlation between haematological toxicity with quality of life in breast cancer patients after first-cycle chemotherapy
Presenter: felix Wijovi
Session: e-Poster Display Session
38P - Evaluation of the prognostic value of innate immunity-related biomarkers in early breast cancer (BC)
Presenter: Veronica Martini
Session: e-Poster Display Session
39P - CSF-1R inhibitor (C019199) enhances antitumor effect in combination with anti-PD-1 therapy on murine breast cancer models
Presenter: Jiani Zheng
Session: e-Poster Display Session
40P - Molecular subtypes and imaging phenotypes of breast cancer: MRI
Presenter: Yulduz Khatamovna
Session: e-Poster Display Session
41P - Mir-223 overexpression is associated with increased expression of EGFR and worse prognosis in Indonesian TNBC patients
Presenter: Ibnu Purwanto
Session: e-Poster Display Session
42P - Impact of germline mutations on breast cancer prognosis in Kazakh population
Presenter: Dilyara Kaidarova
Session: e-Poster Display Session
50P - Efficacy and safety analysis of pyrotinib in lapatinib resistant HER2-positive metastatic breast cancer: A retrospective study
Presenter: Yijia Hua
Session: e-Poster Display Session